Search results
Showing 31 to 45 of 74 results for parkinson
Urinary incontinence in neurological disease: assessment and management (CG148)
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
Falls: assessment and prevention in older people and in people 50 and over at higher risk (NG249)
This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk and incidence of falls, and the associated distress, pain, injury, loss of confidence, loss of independence and mortality.
Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)
Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941
Awaiting development Reference number: GID-TA11481 Expected publication date: TBC
used to treat Parkinson's disease psychosis because it has shown some effectiveness in improving behavioural symptoms in people with...
Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making
Gambling-related harms: identification, assessment and management (NG248)
This guideline covers identifying, assessing and treating gambling-related harms. This includes people aged 18 and over who are experiencing gambling that harms, and people of any age affected by someone close to them who is experiencing gambling that harms.
Evidence-based recommendations on unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor in adults. This involves applying ultrasound to a specific area on 1 side of the brain (thalamus).
View recommendations for HTG474Show all sections
Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making
NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)
YOURmeds for medication support in long-term conditions (MIB289)
NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .
This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS8Show all sections
Sections for QS8
- Quality statements
- Quality statement 1: Assessment
- Quality statement 2: Discussing treatment options
- Quality statement 3: Preventing relapse
- Quality statement 4: Stopping antidepressants
- Quality statement 5: Access to services for adults from minority ethnic backgrounds
- Update information
- About this quality standard
What is the effectiveness of statin therapy in older people?
preventing or promoting other chronic diseases of ageing such as dementia, Parkinson's disease, or age-related macular degeneration....
the population with neurological diseases such as multiple sclerosis, Parkinson's disease and dementia, the rise in temperature with...
Older people with social care needs and multiple long-term conditions (NG22)
This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.